606 related articles for article (PubMed ID: 25701325)
1. PD-1 Restrains Radiotherapy-Induced Abscopal Effect.
Park SS; Dong H; Liu X; Harrington SM; Krco CJ; Grams MP; Mansfield AS; Furutani KM; Olivier KR; Kwon ED
Cancer Immunol Res; 2015 Jun; 3(6):610-9. PubMed ID: 25701325
[TBL] [Abstract][Full Text] [Related]
2. PD-1 or PD-L1 Blockade Restores Antitumor Efficacy Following SSX2 Epitope-Modified DNA Vaccine Immunization.
Rekoske BT; Smith HA; Olson BM; Maricque BB; McNeel DG
Cancer Immunol Res; 2015 Aug; 3(8):946-55. PubMed ID: 26041735
[TBL] [Abstract][Full Text] [Related]
3. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer.
Guo Z; Wang H; Meng F; Li J; Zhang S
J Transl Med; 2015 Jul; 13():247. PubMed ID: 26219551
[TBL] [Abstract][Full Text] [Related]
4. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs.
Allard B; Pommey S; Smyth MJ; Stagg J
Clin Cancer Res; 2013 Oct; 19(20):5626-35. PubMed ID: 23983257
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylserine-targeting antibodies augment the anti-tumorigenic activity of anti-PD-1 therapy by enhancing immune activation and downregulating pro-oncogenic factors induced by T-cell checkpoint inhibition in murine triple-negative breast cancers.
Gray MJ; Gong J; Hatch MM; Nguyen V; Hughes CC; Hutchins JT; Freimark BD
Breast Cancer Res; 2016 May; 18(1):50. PubMed ID: 27169467
[TBL] [Abstract][Full Text] [Related]
6. Abscopal Effects With Hypofractionated Schedules Extending Into the Effector Phase of the Tumor-Specific T-Cell Response.
Zhang X; Niedermann G
Int J Radiat Oncol Biol Phys; 2018 May; 101(1):63-73. PubMed ID: 29534901
[TBL] [Abstract][Full Text] [Related]
7. Cisplatin Facilitates Radiation-Induced Abscopal Effects in Conjunction with PD-1 Checkpoint Blockade Through CXCR3/CXCL10-Mediated T-cell Recruitment.
Luo R; Firat E; Gaedicke S; Guffart E; Watanabe T; Niedermann G
Clin Cancer Res; 2019 Dec; 25(23):7243-7255. PubMed ID: 31506388
[TBL] [Abstract][Full Text] [Related]
8. TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.
Rodríguez-Ruiz ME; Rodríguez I; Mayorga L; Labiano T; Barbes B; Etxeberria I; Ponz-Sarvise M; Azpilikueta A; Bolaños E; Sanmamed MF; Berraondo P; Calvo FA; Barcelos-Hoff MH; Perez-Gracia JL; Melero I
Mol Cancer Ther; 2019 Mar; 18(3):621-631. PubMed ID: 30683810
[TBL] [Abstract][Full Text] [Related]
9. PD-1 blockade enhances radio-immunotherapy efficacy in murine tumor models.
Zhuang Y; Li S; Wang H; Pi J; Xing Y; Li G
J Cancer Res Clin Oncol; 2018 Oct; 144(10):1909-1920. PubMed ID: 30074066
[TBL] [Abstract][Full Text] [Related]
10. Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells.
John LB; Devaud C; Duong CP; Yong CS; Beavis PA; Haynes NM; Chow MT; Smyth MJ; Kershaw MH; Darcy PK
Clin Cancer Res; 2013 Oct; 19(20):5636-46. PubMed ID: 23873688
[TBL] [Abstract][Full Text] [Related]
11. Sequence of αPD-1 relative to local tumor irradiation determines the induction of abscopal antitumor immune responses.
Wei J; Montalvo-Ortiz W; Yu L; Krasco A; Ebstein S; Cortez C; Lowy I; Murphy AJ; Sleeman MA; Skokos D
Sci Immunol; 2021 Apr; 6(58):. PubMed ID: 33837124
[TBL] [Abstract][Full Text] [Related]
12. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice.
Ueha S; Yokochi S; Ishiwata Y; Ogiwara H; Chand K; Nakajima T; Hachiga K; Shichino S; Terashima Y; Toda E; Shand FH; Kakimi K; Ito S; Matsushima K
Cancer Immunol Res; 2015 Jun; 3(6):631-40. PubMed ID: 25711759
[TBL] [Abstract][Full Text] [Related]
13. Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 Blockade.
Dovedi SJ; Cheadle EJ; Popple AL; Poon E; Morrow M; Stewart R; Yusko EC; Sanders CM; Vignali M; Emerson RO; Robins HS; Wilkinson RW; Honeychurch J; Illidge TM
Clin Cancer Res; 2017 Sep; 23(18):5514-5526. PubMed ID: 28533222
[No Abstract] [Full Text] [Related]
14. Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.
Ballesteros-Briones MC; Martisova E; Casales E; Silva-Pilipich N; Buñuales M; Galindo J; Mancheño U; Gorraiz M; Lasarte JJ; Kochan G; Escors D; Sanchez-Paulete AR; Melero I; Prieto J; Hernandez-Alcoceba R; Hervas-Stubbs S; Smerdou C
Mol Ther; 2019 Nov; 27(11):1892-1905. PubMed ID: 31563534
[TBL] [Abstract][Full Text] [Related]
15. Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models.
Onyshchenko K; Luo R; Rao X; Zhang X; Gaedicke S; Grosu AL; Firat E; Niedermann G
Theranostics; 2024; 14(6):2573-2588. PubMed ID: 38646638
[No Abstract] [Full Text] [Related]
16. The Combined Effect of FGFR Inhibition and PD-1 Blockade Promotes Tumor-Intrinsic Induction of Antitumor Immunity.
Palakurthi S; Kuraguchi M; Zacharek SJ; Zudaire E; Huang W; Bonal DM; Liu J; Dhaneshwar A; DePeaux K; Gowaski MR; Bailey D; Regan SN; Ivanova E; Ferrante C; English JM; Khosla A; Beck AH; Rytlewski JA; Sanders C; Laquerre S; Bittinger MA; Kirschmeier PT; Packman K; Janne PA; Moy C; Wong KK; Verona RI; Lorenzi MV
Cancer Immunol Res; 2019 Sep; 7(9):1457-1471. PubMed ID: 31331945
[TBL] [Abstract][Full Text] [Related]
17. Abscopal Effects of Radiotherapy Are Enhanced by Combined Immunostimulatory mAbs and Are Dependent on CD8 T Cells and Crosspriming.
Rodriguez-Ruiz ME; Rodriguez I; Garasa S; Barbes B; Solorzano JL; Perez-Gracia JL; Labiano S; Sanmamed MF; Azpilikueta A; Bolaños E; Sanchez-Paulete AR; Aznar MA; Rouzaut A; Schalper KA; Jure-Kunkel M; Melero I
Cancer Res; 2016 Oct; 76(20):5994-6005. PubMed ID: 27550452
[TBL] [Abstract][Full Text] [Related]
18. Combinatorial immunotherapy of polyinosinic-polycytidylic acid and blockade of programmed death-ligand 1 induce effective CD8 T-cell responses against established tumors.
Nagato T; Lee YR; Harabuchi Y; Celis E
Clin Cancer Res; 2014 Mar; 20(5):1223-34. PubMed ID: 24389326
[TBL] [Abstract][Full Text] [Related]
19. TIGIT and PD-1 impair tumor antigen-specific CD8⁺ T cells in melanoma patients.
Chauvin JM; Pagliano O; Fourcade J; Sun Z; Wang H; Sander C; Kirkwood JM; Chen TH; Maurer M; Korman AJ; Zarour HM
J Clin Invest; 2015 May; 125(5):2046-58. PubMed ID: 25866972
[TBL] [Abstract][Full Text] [Related]
20. PD-1 upregulated on regulatory T cells during chronic virus infection enhances the suppression of CD8+ T cell immune response via the interaction with PD-L1 expressed on CD8+ T cells.
Park HJ; Park JS; Jeong YH; Son J; Ban YH; Lee BH; Chen L; Chang J; Chung DH; Choi I; Ha SJ
J Immunol; 2015 Jun; 194(12):5801-11. PubMed ID: 25934860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]